Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306434 | 0.84 | TDP1 (0.53) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL14404775 | 0.83 | CTSK (0.51) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL14085304 | 0.83 | PTPN11 (0.48) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL14952767 | 0.82 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL12378924 | 0.82 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL24199859 | 0.82 | PTPN11 (0.47) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL2143910 | 0.82 | PTPN11 (0.47) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL5057593 | 0.82 | PTPN11 (0.47) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL13306431 | 0.82 | PTPN11 (0.47) | TDP1PTPN11MEN1GAAKMT2A | |
| SCHEMBL10223350 | 0.82 | PTPN11 (0.47) | TDP1PTPN11MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731219-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | Promega Corporation (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250003974-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | PROMEGA CORPORATION | 2025-01-02 | — | — | US | disclosed |
| WO-2024263837-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | PROMEGA CORPORATION (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-8188216-B2 | Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery | TRANZYME PHARMA INC. (CA) | 2012-05-29 | — | — | US | disclosed |
| US-20120046441-A1 | Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2012-02-23 | — | — | US | disclosed |
| US-20120046441-A1 | Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2012-02-23 | — | — | US | disclosed |
| US-8008440-B2 | Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery | TRANZYME PHARMA INC. (CA) | 2011-08-30 | — | — | US | disclosed |
| US-20070117154-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2007-05-24 | — | — | US | disclosed |
| US-7169899-B1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | TRANZYME PHARMA INC. (CA) | 2007-01-30 | — | — | US | disclosed |
| EP-1218403-B1 | COMBINATORIAL SYNTHESIS OF LIBRARIES OF MACROCYCLIC COMPOUNDS USEFUL IN DRUG DISCOVERY | TRANZYME PHARMA INC (CA) | 2006-11-29 | — | — | EP | disclosed |
| US-20050049234-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | NEOKIMIA INC. (CA) | 2005-03-03 | — | — | US | disclosed |
| EP-1218403-A2 | COMBINATORIAL SYNTHESIS OF LIBRARIES OF MACROCYCLIC COMPOUNDS USEFUL IN DRUG DISCOVERY | Neokimia, Inc. (CA) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025257-A2 | COMBINATORIAL SYNTHESIS OF LIBRARIES OF MACROCYCLIC COMPOUNDS USEFUL IN DRUG DISCOVERY | NEOKIMIA, INC. (CA) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049234-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | F2, BCAT1, CTRL | TDP1 3101/4885PTPN11 2655/4885MEN1 1302/4885 |
| US-20120046441-A1 | Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery | COASY, SCO2, CCNO | TDP1 3682/4885PTPN11 1827/4885MEN1 3174/4885 |
| US-20070117154-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | F2, BCAT1, DAO | TDP1 3272/4885PTPN11 2803/4885MEN1 1329/4885 |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | TDP1 4168/4885PTPN11 397/4885MEN1 1710/4885 |
| US-20250003974-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | POLQ, POLB, POLM | TDP1 45/4885PTPN11 4843/4885MEN1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.